FP7Staff exchange2008–2012

EIMID-IAPP · European Initiative for basic research in Microbiology and Infectious Diseases - IAPP

FP7 — People (Marie Curie Actions)

Duration
2008-12-01 → 2012-11-30
EU contribution
€2,172,806
Participants
5
Scheme
MC-IAPP

Lines connect the coordinator with its partners.

Results in brief

European initiative for basic research in microbiology and infectious diseases

The EIMID-IAPP training programme is part of the European Initiative for Basic Research in Microbiology and Infectious Diseases (EIMID), created in 2003 by scientists of five European centres of excellence (the Max Planck Institute for Infection Biology in Berlin, the CMMI in London, the Institut Pasteur in Paris, the Karolinska Institutet in Stockholm; and the vaccine company Novartis V&D in Siena). The EIMID initiative brings together scientists from each of the institutes and promotes collaborations and scientific interactions. EIMID-IAPP aims to implement the industry-academia cooperation through an integrated young staff researchers exchange programme between the industrial partner and the four academic institutions. The global goal of the collaborative research and development project is on novel therapeutic approaches against infectious diseases, with a particular emphasis on bacterial infections affecting mucosal surface (gut, stomach, lung), and for the development novel vaccines. The scientific workplan is divided into two areas: (i) discovering key antigens that are essential for infection and (ii) identifying key bacterial genes essential for survival / growth / colonisation / virulence expression in in vivo conditions, the products of which would become targets for new families of vaccines to be discovered in the context of the initiative. The project involved eight secondments of researchers, seven from the industrial partner to the four academic partners and one from an academic partner to the industrial partner. In addition, each partner has recruited one (or two in the MPIIB case) researcher to the programme. The projects included the following: 1. A study of gene regulation in Shigella in order to understand the mechanisms that govern survival and virulence gene expression in the lower intestine, in particular the influence of anaerobiosis and oxidative stress. Several proteins that control the transport of proteins to the bacterial surface have been shown to be regulated when oxygen levels are low. Some of these are likely to be important for survival in the oxygen poor environment of the gut and hence may be potential vaccine candidates. 2. Studies on the interaction of Shigella with host immune cells that have shown that the pathogen is capable of interfering with an appropriate immune response. This in part explains why Shigella is able to evade elimination by the host immune system. 3. Studies on the regulation of expression of a virulence factor of Neisseria meningitidis that is an important component of a novel vaccine against meningitis. This vaccine has recently been approved by the European Medicines Evaluation Agency (EMEA) and it was important to understand whether the antigen is expressed during disease and how it is regulated. In addition, the structure and regulation of adhesive pili that are important for bacterial colonisation were studied. 4. Studies on the filamentous structures on the surface of Streptococcus pneumoniae that are involved in the adhesion of this pathogen to the cells of the respiratory mucosa. It has been shown that these structures also interfere with the action of cells of the host innate immune system. 5. Studies on the effect of infection of the stomach by Helicobacter pilori on the cells of the gastric mucosa that have documented several changes in the genes expressed after infection. Some of these changes may be involved in the pathogens ability to cause gastric cancer. These studies have led to insights into how mucosal pathogens cause disease. A better understanding of the disease process and the interaction with the host immune system will lead to the design of new or better vaccines capable of preventing infection and / or disease. Furthermore, the close interactions between the academic and industry laboratories have led to more collaborations that will strengthen the field of microbiology in Europe. The website of the project is: http://www.eimid.org/projects/iapp/index.html

Data: CORDIS, © European Union

Project objective

The EIMID-IAPP training programme is part of the European Initiative for Basic Research in Microbiology and Infectious Diseases (EIMID), created in 2003 by scientists of five European centres of excellence (the Max Planck Institute for Infection Biology in Berlin, the CMMI at Imperial College in London, the Institut Pasteur in Paris, the Karolinska Institutet in Stockholm; and the vaccine company Novartis in Siena). By building a strong coalition among these institutes, EIMID aims at setting the basis for a future no-wall European Institute of Microbiology and Infectious Diseases, as part of the European Research Area (ERA). EIMID-IAPP aims at implementing the Industry-Academia cooperation through an integrated programme of exchange of young researchers between the industrial partner and the four academic institutions. The goal of the collaborative project is the development of Novel Therapeutic Approaches against Infectious Diseases, with particular emphasis to drug-based and vaccine-based therapies for bacterial infections affecting mucosal surfaces. Four researchers will be seconded from the industrial partner to the four academic institutions and vice-versa. Each secondment will be for two years (with a six month intermission for intermediate knowledge transfer to the mother institution), and the seconded staff between two institutions will investigate complementary aspects of the same project sub-area. Each institution will also recruit an experienced researcher for two years, to acquire new expertise and technologies necessary to the project development. A series of informal discussions, and annual general meetings, will allow constant exchange of information and efficient project steering. This activity of Industry-Academia exchange fulfils the EIMID goals of 1) harmonising European research programmes, so as to achieve a critical mass on relevant topics. 2) fostering exchange of scientists, particularly at the doctoral and post-doctoral levels.

Original text from CORDIS.

Participants

  • GLAXOSMITHKLINE VACCINES SRL · SIENACoordinatorItaly
  • IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE · LondonUnited Kingdom
  • INSTITUT PASTEUR · ParisFrance
  • KAROLINSKA INSTITUTET · STOCKHOLMSweden
  • MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV · MUNCHENGermany

Links

Data: CORDIS, © European Union